NCE-1 Intelligence & Market Opportunity

Livdelzi

Seladelpar

Hepatoprotective Agents

Capsule

Livdelzi is used to treat primary biliary cholangitis (PBC). The purpose of Livdelzi is to efficiently target PPARδ, a peroxisome proliferator-activated receptor delta that inhibits the formation of bile acids.

Approval Date

14-Aug-24

NCE-1 Date

14-Aug-28

NCE Date

14-Aug-29

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

713

2027

1059

2028

1399

2029

1654

2030

1849

2031

1756

2032

1801

Molecule profile

Details & specifications

Molecule

Seladelpar

Innovator

GILEAD SCIENCES INC

Dosage Form

Capsule

Strength

10 mg

Therapeutic Category

Hepatoprotective Agents

Usage

To treat primary biliary cholangitis (PBC)

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.